我武生物
(300357)
| 流通市值：94.25亿 | | | 总市值：101.94亿 |
| 流通股本：4.84亿 | | | 总股本：5.24亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 730,238,304.07 | 429,257,047.81 | 216,249,528.11 | 848,190,443.3 |
| 营业收入 | 730,238,304.07 | 429,257,047.81 | 216,249,528.11 | 848,190,443.3 |
| 二、营业总成本 | 427,571,052.51 | 265,408,191.17 | 132,389,079.88 | 513,936,550.27 |
| 营业成本 | 34,634,787.12 | 21,687,521.14 | 10,416,061.8 | 40,189,443.39 |
| 税金及附加 | 4,657,424.06 | 3,500,831.66 | 1,292,949.08 | 5,757,458.02 |
| 销售费用 | 270,793,761.25 | 163,437,646.75 | 80,961,800.81 | 323,167,128.64 |
| 管理费用 | 52,758,384.8 | 33,647,865.87 | 16,458,144.99 | 62,108,852.94 |
| 研发费用 | 87,862,042.99 | 59,253,401.99 | 30,563,652.07 | 112,196,011.42 |
| 财务费用 | -23,135,347.71 | -16,119,076.24 | -7,303,528.87 | -29,482,344.14 |
| 其中:利息费用 | 899,572.95 | 619,422.91 | 319,261.87 | 1,308,407.77 |
| 其中:利息收入 | 24,233,008.41 | 16,904,748.52 | 7,764,062.21 | 30,957,179.18 |
| 加:公允价值变动收益 | -763,407.78 | 30,176.23 | 400,180.79 | -666,941.56 |
| 加:投资收益 | 6,482,593.58 | -53,108.98 | -363,771.21 | 1,910,702.96 |
| 资产处置收益 | 568,926.85 | 353,473.3 | 284,607.11 | - |
| 资产减值损失(新) | - | - | - | -472,549.79 |
| 信用减值损失(新) | -4,921,945.92 | -2,473,194.07 | -1,882,028.87 | 903,313.21 |
| 其他收益 | 12,145,650.34 | 10,728,407.28 | 5,706,164.22 | 9,044,935.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 316,179,068.63 | 172,434,610.4 | 88,005,600.27 | 344,973,353.01 |
| 加:营业外收入 | 354,565.55 | 235,092.35 | 117,418.65 | 1,777,892.77 |
| 减:营业外支出 | 3,009,469.52 | 2,171,589.09 | 327,397.08 | 795,742.84 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 313,524,164.66 | 170,498,113.66 | 87,795,621.84 | 345,955,502.94 |
| 减:所得税费用 | 51,026,066.64 | 27,875,851.94 | 13,879,737.29 | 50,433,428.86 |
| 六、净利润 | 262,498,098.02 | 142,622,261.72 | 73,915,884.55 | 295,522,074.08 |
| 持续经营净利润 | 262,498,098.02 | 142,622,261.72 | 73,915,884.55 | 295,522,074.08 |
| 归属于母公司股东的净利润 | 272,253,993.52 | 149,230,994.02 | 77,207,320.73 | 310,184,878.02 |
| 少数股东损益 | -9,755,895.5 | -6,608,732.3 | -3,291,436.18 | -14,662,803.94 |
| (一)基本每股收益 | 0.52 | 0.29 | 0.15 | 0.59 |
| (二)稀释每股收益 | 0.52 | 0.29 | 0.15 | 0.59 |
| 八、其他综合收益 | -1,421.66 | 5,375,171.48 | 5,347,832.68 | 4,321.02 |
| 归属于母公司股东的其他综合收益 | -1,421.66 | 5,375,171.48 | 5,347,832.68 | 4,321.02 |
| 九、综合收益总额 | 262,496,676.36 | 147,997,433.2 | 79,263,717.23 | 295,526,395.1 |
| 归属于母公司股东的综合收益总额 | 272,252,571.86 | 154,606,165.5 | 82,555,153.41 | 310,189,199.04 |
| 归属于少数股东的综合收益总额 | -9,755,895.5 | -6,608,732.3 | -3,291,436.18 | -14,662,803.94 |
| 公告日期 | 2024-10-24 | 2024-08-23 | 2024-04-19 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |